Skip to main content

Clinical Trials Using Methotrexate

Review the clinical trials studying methotrexate on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 71

Adding Dasatinib or Venetoclax to Standard Chemotherapy for the Treatment in Children with T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoma or Mixed Phenotype Acute Leukemia, the SJALL23T Trial
Status: Active
Location: 3 locations
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients with Acute Leukemia or Myelodysplastic Syndrome
Status: Active
Location: 3 locations
Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma
Status: Active
Location: 3 locations
Ruxolitinib in Combination with Standard Chemotherapy in Treating Adolescents and Young Adults with Ph-Like Acute Lymphoblastic Leukemia
Status: Active
Location: 3 locations
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
Status: Active
Location: 3 locations
Risk Categorization for Treatment Assignment in Children and Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma, the INITIALL Trial
Status: Active
Location: 3 locations
High-Dose Methotrexate in Treating Patients with Breast Cancer and Leptomeningeal Metastasis
Status: Active
Location: 2 locations
Inotuzumab Ozogamicin in Treating Patients with MRD Positive CD22+ Relapsed B Cell Acute Lymphoblastic Lymphoma
Status: Active
Location: 2 locations
Inotuzumab Ozogamicin and Blinatumomab with Standard Chemotherapy in Treating Newly Diagnosed Patients with B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Status: Active
Location: 2 locations
Pembrolizumab in Combination with Chemotherapy for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma
Status: Active
Location: 2 locations
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Low-Dose Methotrexate for the Treatment of Myeloproliferative Neoplasms, TREATMORE Trial
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Abatacept Extended Dosing Compared to Abatacept Short-Term Dosing for the Prevention of Graft versus Host Disease, ABA3 Study
Status: Active
Location: Boston Children's Hospital, Boston, Massachusetts
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
2 Step ATG with Preparative Chemotherapy and Methotrexate for the Prevention of Acute GVHD for Patients Undergoing Myeloablative Allogeneic Stem Cell Transplant for Hematopoietic Disorders
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Durvalumab and Standard Chemotherapy for the Treatment of Lymph Node Positive Bladder Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CPX-351 (VYXEOS) for the Treatment of Secondary Myeloid Neoplasms in Patients Under 22 Years Old
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Anti-Thymocyte Globulin added to Tacrolimus and Methotrexate for Reducing Graft Versus Host Disease after Hematopoietic Stem Cell Transplant for Hematologic Cancers
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Venetoclax, Tagraxofusp, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients with Philadelphia Chromosome-Positive and/ or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combination Chemotherapy and Nelarabine in Treating Patients with T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Mini Hyper-CVD with Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for the Treatment of Relapsed B-Cell Acute Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Asparaginase Erwinia Chrysanthemi with Chemotherapy for the Treatment of High-Risk Adults with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Partial Cystectomy and Extended Pelvic Lymph Node Dissection with Standard of Care Systemic Therapy for the Treatment of Muscle-Invasive Bladder Cancer
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients with B Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas